scorecardresearch

Nigeria introduces Bharat Biotech’s ROTAVAC vaccine for immunisation in children

At present, Nigeria accounts for 14 percent of all childhood rotavirus deaths globally, making it the country with the second-highest number of rotavirus deaths in the world.

Nigeria introduces Bharat Biotech’s ROTAVAC vaccine for immunisation in children
Rotavirus is one of the leading causes of diarrheal disease in the world and is responsible for over 40 percent of diarrhoea in children. (File)

Bharat Biotech International Limited (BBIL) on Wednesday announced its rotavirus oral vaccine ROTAVAC has been introduced by Nigeria to immunise its children from the life-threatening diarrhoeal disease that affects millions of children across the world.

At present, Nigeria accounts for 14 percent of all childhood rotavirus deaths globally, making it the country with the second-highest number of rotavirus deaths in the world. Rotavirus infection causes about 50,000 child fatalities under the age of five each year in Nigeria.

ALSO READ | Bharat Biotech concludes clinical trials of intranasal COVID-19 vaccine; Says it is safe and immunogenic

“Decades of research and product development have resulted in ROTAVAC. This vaccine is now available in several countries across Asia, Africa, Latin America and the Middle East. We are proud to state that novel vaccines from India are saving lives worldwide. We are committed to supporting, and reducing the infectious disease burden amongst children in the developing world, and to ensure nations like Nigeria in the African continent, have access to cost-effective world-class interventions for infants and vulnerable populations. ROTAVAC® is safe and effective at preventing diarrheal disease caused by the Rotavirus,” Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said in a statement.

Ella also stated that Bharat Biotech will continue to play its role in researching, developing, and manufacturing novel vaccines, to lower the morbidity and mortality from infectious diseases and contribute towards the achievement of universal vaccine access.

Rotavirus is one of the leading causes of diarrheal disease in the world and is responsible for over 40 percent of diarrhoea in children. It accounts for about 215,000 of the 525,000-under-5 mortality worldwide each year that are attributed to diarrheal diseases, making it the most common cause of severe diarrhoea.

In January 2018, ROTAVAC received WHO-Prequalification. The company claims that Bharat Biotech developed the first generation, rotavirus vaccine, Rotavac under a Public-Private Partnership with the Department of Biotechnology, the Government of India, and 16 other international partners, making it the largest ever social innovation project for public health.

ALSO READ | Bharat Biotech expects DGCI’s nod for intranasal COVID-19 vaccine this month

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.